

Result of AGM

Released : 17/05/2018

RNS Number : 45580

Arix Bioscience Plc

17 May 2018

Arix Bioscience Plc

Results of Annual General Meeting

LONDON, 17 May, 2018: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience" or the "Company"), a global healthcare and life science company supporting medical innovation, announces that its Annual General Meeting (the "Meeting") was held on Thursday 17 May 2018 at 11am (BST). At the Meeting, the ordinary and special resolutions set out in the Notice of the Annual General Meeting dated 20 April 2018 (the "Notice of AGM"), were proposed and passed by way of a poll. Resolutions 1 to 15 were passed as ordinary resolutions. Resolutions 16 to 19 were passed as special resolutions.

Full details of the poll results are set out below and will also be available on the Company's website www.arixbioscience.com.

| No | RESOLUTION | VOTES FOR | % | VOTES AGAINST | % | TOTAL VOTES | % of ISC VOTED | VOTES WITHHELD |
|----|--|------------|--------|---------------|------|-------------|----------------|----------------|
| 1 | To receive the Directors' report and the accounts for the Company for the year ended 31 December 2017 | 56,584,402 | 100.00 | 0 | 0.00 | 56,584,402 | 41.99% | 0 |
| 2 | To approved the Directors' Remuneration Report for the year ended 31 December 2017 | 50,988,886 | 90.12 | 5,591,495 | 9.88 | 56,580,381 | 41.98% | 4,020 |
| 3 | To re-elect Dr Joseph Anderson as a Director | 56,584,402 | 100.00 | 0 | 0.00 | 56,584,402 | 41.99% | 0 |
| 4 | To re-elect Professor Sir Christoher Evans as a Director | 56,584,402 | 100.00 | 0 | 0.00 | 56,584,402 | 41.99% | 0 |
| 5 | To re-elect Dr Franz Humer as a Director | 51,655,214 | 91.29 | 4,929,188 | 8.71 | 56,584,402 | 41.99% | 0 |
| 6 | To re-elect Lord John Hutton of Furness as a Director | 54,810,619 | 96.87 | 1,773,783 | 3.13 | 56,584,402 | 41.99% | 0 |
| 7 | To re-elect Professor Trevor Jones as a Director | 56,584,402 | 100.00 | 0 | 0.00 | 56,584,402 | 41.99% | 0 |
| 8 | To re-elect Jonathan Peacock as a Director | 54,526,217 | 96.36 | 2,058,185 | 3.64 | 56,584,402 | 41.99% | 0 |
| 9 | To re-elect James Rawlingson as a Director | 56,584,402 | 100.00 | 0 | 0.00 | 56,584,402 | 41.99% | 0 |
| 10 | To re-elect David U'Prichard as a Director | 55,183,865 | 97.53 | 1,399,000 | 2.47 | 56,582,865 | 41.99% | 1,537 |
| 11 | To elect Meghan FitzGerald as a Director | 56,584,402 | 100.00 | 0 | 0.00 | 56,584,402 | 41.99% | 0 |
| 12 | To elect Giles Kerr as a Director | 56,582,865 | 100.00 | 0 | 0.00 | 56,582,865 | 41.99% | 1,537 |
| 13 | To re-appoint PwC LLP as auditors of the Company | 55,185,402 | 97.53 | 1,399,000 | 2.47 | 56,584,402 | 41.99% | 0 |
| 14 | To authorise the Audit & Risk Committee of the Company to fix the remuneration of the auditors | 56,584,402 | 100.00 | 0 | 0.00 | 56,584,402 | 41.99% | 0 |
| 15 | To authorise the Directors to allot shares | 55,618,631 | 100.00 | 2,198 | 0.00 | 55,620,829 | 41.27% | 963,573 |
| 16 | To authorise the Directors to disapply statutory pre-emption rights in respect of 5% of the Company's issued share capital | 53,013,611 | 95.32 | 2,605,020 | 4.68 | 55,618,631 | 41.27% | 965,771 |
| 17 | To authorise the Directors to disapply statutory pre-emption rights in respect of an additional 5% of the Company's issued share capital | 51,614,611 | 92.80 | 4,004,020 | 7.20 | 55,618,631 | 41.27% | 965,771 |
| 18 | To authorise the Company to buy back shares | 54,215,987 | 97.48 | 1,403,929 | 2.52 | 55,619,916 | 41.27% | 964,486 |
| 19 | To authorise the Directors to call a general meeting other than an annual general meeting on not less than 14 clear days' notice | 56,581,832 | 100.00 | 2,570 | 0.00 | 56,584,402 | 41.99% | 0 |

Notes:

- Any proxy arrangement which gave discretion to the Chairman has been included in the "for" totals.
- A "Vote withheld" is not a vote in law and is not counted in the calculation of the percentage of shares voted "For" or "Against" any resolution.
- The number of voting shares in issue at 6:00 p.m. on 15 May 2018 was 134,764,018 (the "Share Capital"). The Company does not hold any shares in treasury.

In accordance with Listing Rule 9.6.2, copies of resolutions passed at the Meeting concerning items other than ordinary business will shortly be available for inspection on the National Storage Mechanism, which can be accessed at www.hemscott.com/nsm.do

ENDS

Enquiries

For more information on Arix, please contact:

Arix Bioscience plc
Robert Lyne, Company Secretary
+44 (0) 20 7290 1055

Charlotte Parry, Investor Relations Manager
+44 (0)20 7290 1072
charlotte@arixbioscience.com

Consilium Strategic Communications
Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan
+44 (0)20 3709 5700
arix@consilium-comms.com

About Arix Bioscience plc

Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.

For further information, please visit www.arixbioscience.com

This information is provided by RNS
The company news service from the London Stock Exchange

END

RAGFKODDBBKDOPD